Logo

Bernard Tobin

Dec 22, 2014

Myriad Genetics has appointed Bernard Tobin as president of Crescendo Bioscience. Tobin joins Myriad from Amgen, where over the past seven years he has held various leadership roles, including executive director of national accounts, general manager of theNetherlandsandBrazil, as well as global head of commercial excellence. Before Amgen, Tobin had worked at Eli Lilly and Co.

Tobin will take over for William Hagstrom and report to Myriad CEO Peter Meldrum. Hagstrom has decided to leave Crescendo to pursue startup and social venture opportunities. He will stay with the company until Jan. 2, 2015, and Tobin's appointment will be effective as of Jan. 5.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.